Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/02/2022* -- Results Q3 2022 -- 4.41 --
11/02/2022* 14:00 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 4.65 4.33 7.28%
08/04/2022 17:00 EST Earnings Call Q2 2022 -- -- --
04/27/2022 -- Results Q1 2022 4.25 4.12 3.17%
04/27/2022 17:00 EST Earnings Call Q1 2022 -- -- --
02/07/2022 -- Results Q4 2021 4.36 4.01 8.76%
02/07/2022 16:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/02/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since -8.03%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
URL https://www.amgen.com
Investor Relations URL https://investors.amgen.com
HQ State/Province California
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Aug. 17, 2022

Dividends

Dividend Per Share (TTM) 7.40
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 2.289
Yield to Sector 1.822
Yield to Industry 0.9095
Last Dividend Amt. 1.94
Dividend Frequency Quarterly
Last Ex-Dividend Date Aug. 17, 2022
Yield (TTM) 3.36%
Forward Yield 3.44%
Payout Ratio 62.45%
Cash Payout Ratio 49.16%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) Yes

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
3.97%
-7.55%
22.25%
15.17%
27.62%
-2.00%
0.87%
2.65%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-23.87%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
15.20%
19.24%
-13.50%
7.72%
-12.91%
27.86%
0.39%
2.89%
16.68%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-24.15%
-6.46%
9.88%
60.13%
-0.98%
1.50%
27.61%
32.40%
2.00%
As of September 30, 2022.

Profile

Edit
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
URL https://www.amgen.com
Investor Relations URL https://investors.amgen.com
HQ State/Province California
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Aug. 17, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
IBB 589.55M USD 7.80%
DIA 1.320B USD 5.12%
SCHD 1.438B USD 3.98%
VPMCX 2.252B USD 3.76%
VPCCX 355.09M USD 3.44%
VHCOX 526.48M USD 3.15%
XLV 981.93M USD 2.65%
VHCIX 435.83M USD 2.35%
VHT 435.83M USD 2.35%
CMLFX 1.223B USD 1.48%
QQQ 1.802B USD 1.19%
CIRFX 1.154B USD 1.15%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter AMGN Tweets